Trial Profile
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Eptinezumab (Primary)
- Indications Migraine; Secondary headache disorders
- Focus Registrational; Therapeutic Use
- Acronyms PROMISE 2
- Sponsors Alder Biopharmaceuticals
- 28 Jun 2023 Results assessing clinical impact of reduced headache frequency to <4 monthly headache days (MHDs) as a treatment-related migraine prevention target goal, published in the Pain and Therapy.
- 27 Apr 2023 Results from PROMISE-1 and PROMISE-2 ; demonstrating the lack of a wearing off effect with eptinezumab in preventive migraine treatment, presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 27 Apr 2023 Subgroup analysis results ( N=1072) presented at the 75th Annual Meeting of the American Academy of Neurology 2023.